“Psoriasis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Psoriasis Market.
The Psoriasis Pipeline report embraces in-depth commercial, regulatory, and Psoriasis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Psoriasis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights into the emerging therapies for Psoriasis treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Psoriasis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Psoriasis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Psoriasis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Psoriasis therapeutic market.
Psoriasis Therapeutics Landscape
Treatment modalities are chosen based on disease severity, relevant comorbidities, patient preference (including cost and convenience), efficacy, and evaluation of individual patient response. Although there is no cure for psoriasis, there are multiple effective treatment options, and topical therapy is the standard of care for treatment. Mild to moderate psoriasis can be treated topically with a combination of glucocorticoids, vitamin D analogues, and phototherapy. Systemic treatment, which includes immunosuppressants and biologics, is required in moderate-to-severe cases.
In recent years, several technologies have been developed to enhance the efficacy and safety of topical drug therapy. Furthermore, new drug carriers offer the opportunity to introduce new molecules into topical psoriasis therapy. For these purposes, vesicular drug delivery systems including niosomes, proniosomes, liposomes and transferosomes, nonvesicular drug delivery systems such as foams, gels, and nanoparticles have been developed.
Despite its considerable effect on the quality of life, psoriasis is underdiagnosed and undertreated. A better understanding of the disease and an increase in available treatment options will aid in optimal management improving patient outcomes in the coming years.
In September 2022, the US FDA approved Boehringer Ingelheim’s spesolimab (Spevigo) as a treatment for generalized pustular psoriasis (GPP) flares in adults. Additionally, in July 2022, the US FDA approved the first and only topical PdE4 inhibitor for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis.
There are approx. 80+ key companies developing therapies for Psoriasis. Currently, Biocad is leading the therapeutics market with its Psoriasis drug candidates in the most advanced stage of clinical development.
Psoriasis Companies Actively Working in the Therapeutic Market Include:
Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and many others
Emerging and Marketed Psoriasis Drugs Covered in the Report Include:
Topical roflumilast: Arcutis Biotherapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Psoriasis Companies Working in the Market @
Analysis of Emerging Psoriasis Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Learn How the Psoriasis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Psoriasis Treatment Patterns
4. Psoriasis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Psoriasis Late Stage Products (Phase-III)
7. Psoriasis Mid-Stage Products (Phase-II)
8. Psoriasis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Psoriasis Discontinued Products
13. Psoriasis Product Profiles
14. Major Psoriasis Companies in the Market
15. Key Products in the Psoriasis Therapeutics Segment
16. Dormant and Discontinued Products
17. Psoriasis Unmet Needs
18. Psoriasis Future Perspectives
19. Psoriasis Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Alpha-Antitrypsin Deficiency Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Alpha-Antitrypsin Deficiency market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Alpha-Antitrypsin Deficiency market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States